TXMD TherapeuticsMD Inc
TherapeuticsMD, Inc. is a pharmaceutical company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Company profile
Ticker
TXMD
Exchange
Website
CEO
Robert G. Finizio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMHN, Inc., CROFF ENTERPRISES INC, CROFF OIL CO
SEC CIK
Corporate docs
IRS number
870233535
TXMD stock data
()
Investment data
Securities sold
Number of investors
Calendar
9 Nov 20
3 Dec 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 24 Nov 20 | Finizio Robert G | RSU Common Stock | Grant | Aquire A | No | 0 | 1 | 0 | 1 |
| 24 Nov 20 | Milligan John C.K. IV | RSU Common Stock | Grant | Aquire A | No | 0 | 360,000 | 0 | 360,000 |
| 24 Nov 20 | Donegan Michael C | RSU Common Stock | Grant | Aquire A | No | 0 | 230,000 | 0 | 230,000 |
Institutional ownership Q3 2020
53.2% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 142 |
| Opened positions | 15 |
| Closed positions | 22 |
| Increased positions | 32 |
| Reduced positions | 48 |
13F shares |
Current |
|---|---|
| Total value | 394.19M |
| Total shares | 157.53M |
| Total puts | 874.5K |
| Total calls | 838.3K |
| Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
|---|---|---|
| TROW T. Rowe Price | 19.06M | $30.11M |
| BLK Blackrock | 18.69M | $29.53M |
| FMR | 14.31M | $22.61M |
| Rubric Capital Management | 13.93M | $22.01M |
| JPM JPMorgan Chase & Co. | 13.17M | $21.2M |
| Vanguard | 12.77M | $20.18M |
| C WorldWide Group Holding A/S | 6.19M | $9.78M |
| GMT Capital | 5.99M | $9.46M |
| STT State Street | 4.45M | $7.03M |
| Sanders Morris Harris | 4.3M | $6.79M |
Financial report summary
?Competition
Mylan • Pfizer • Amag Pharmaceuticals • Allergan • Agile Therapeutics • VMS • Allergan • Mylan II B.V. • Amneal Pharmaceuticals • Amneal Pharmaceuticals Inc -
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
beneficial, buyer, commended, consummate, criminal, defending, depression, diligence, disadvantage, disposition, Dispute, diversion, divest, divestiture, divesture, drew, effectuate, expose, FDRR, fifteen, flexibility, governmental, heighten, indemnification, jurisdiction, liable, merge, modification, opposed, placement, presence, prevail, proceed, proportionately, refinance, relaunched, Resolution, restructuring, revert, slower, Street, subsided, telehealth, temporarily, therapeutic, trance, unable, unlawful, unsuccessful, vii, viii, vulnerability, withdrew
Removed:
accreted, convertible, curtail, growing, manage, relinquish, thereunder, valuable
Financial reports
10-Q
2020 Q3
Quarterly report
9 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K/A
2019 FY
Annual report (amended)
29 Apr 20
10-K
2019 FY
Annual report
24 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
Current reports
8-K
Entry into a Material Definitive Agreement
27 Nov 20
8-K
Entry into a Material Definitive Agreement
13 Nov 20
8-K
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
9 Nov 20
8-K
Regulation FD Disclosure
14 Sep 20
8-K
TherapeuticsMD® Announces Second Quarter 2020 Financial Results
6 Aug 20
8-K
Regulation FD Disclosure
23 Jun 20
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Departure of Directors or Certain Officers
1 Jun 20
8-K
Termination of a Material Definitive Agreement
15 May 20
8-K
Regulation FD Disclosure
13 May 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
27 Nov 20
424B2
Prospectus for primary offering
12 Nov 20
424B5
Prospectus supplement for primary offering
9 Nov 20
D
$7.5M in options / securities to be acquired, sold $7.5M, 3 investors
14 Aug 20
S-8
Registration of securities for employees
7 Aug 20
POS AM
Prospectus update (post-effective amendment)
24 Feb 20
424B2
Prospectus for primary offering
25 Oct 19
FWP
Free writing prospectus
24 Oct 19
FWP
Free writing prospectus
23 Oct 19
424B5
Prospectus supplement for primary offering
23 Oct 19
Proxies
DEFA14A
Additional proxy soliciting materials
4 May 20
DEF 14A
Definitive proxy
4 May 20
PRER14A
Preliminary revised proxy
22 Apr 20
PRE 14A
Preliminary proxy
13 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEFA14A
Additional proxy soliciting materials
27 Apr 18
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
25 Apr 17
Other
EFFECT
Notice of effectiveness
6 May 20
CT ORDER
Confidential treatment order
10 Apr 19
CT ORDER
Confidential treatment order
12 Dec 18
CT ORDER
Confidential treatment order
21 Aug 18
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
31 Jan 17
UPLOAD
Letter from SEC
25 Jan 17
CORRESP
Correspondence with SEC
29 Dec 16
UPLOAD
Letter from SEC
15 Dec 16
EFFECT
Notice of effectiveness
17 Nov 15
Ownership
4
TherapeuticsMD / Michael C Donegan ownership change
27 Nov 20
4
TherapeuticsMD / John C.K. IV Milligan ownership change
27 Nov 20
4
TherapeuticsMD / Robert G Finizio ownership change
27 Nov 20
4/A
TherapeuticsMD / James DArecca ownership change
8 Aug 20
3
TherapeuticsMD / EDWARD BORKOWSKI ownership change
8 Aug 20
3
TherapeuticsMD / Marlan D Walker ownership change
8 Aug 20
4
TherapeuticsMD / PAUL BISARO ownership change
19 Jun 20
4
TherapeuticsMD / Tommy G Thompson ownership change
19 Jun 20
4
TherapeuticsMD / Angus C. Russell ownership change
19 Jun 20
4
TherapeuticsMD / Gail K Naughton ownership change
19 Jun 20
Patents
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
17 Nov 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
APP
Utility
Soluble Estradiol Capsule for Vaginal Insertion
12 Nov 20
According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided.
APP
Utility
CorrectedVaginal Inserted Estradiol Pharmaceutical Compositions and Methods
29 Oct 20
Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
GRANT
Utility
Vaginal inserted estradiol pharmaceutical compositions and methods
20 Oct 20
According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided.
GRANT
Utility
Natural combination hormone replacement formulations and therapies
20 Oct 20
Pharmaceutical formulations for co-administering estradiol and progesterone are provided herein.